For Parkinson's disease (PD) experiencing "off" episodes. Sold as Nourianz. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Istradefylline (sold as Nourianz), first approved Aug 27, 2019, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Nourianz | Part D | $53.6M | +6% | 3,299 |
| VG081821AC Tablets for Early to Mid-stage Parkinson's DiseaseParkinson Disease (PD) · Zhejiang Vimgreen Pharmaceuticals, Ltd. | Phase 2 / Phase 3 | Recruiting | Jul 24, 2026 |
| Enhancing Rehabilitation in Aging Study (ERAS)Adults · University of Florida | Phase 1 / Phase 2 | Not yet recruiting | Jul 15, 2026 |
| Adenosine 2A Receptor Antagonism and AIH in ALSALS · University of Florida | Phase 1 / Phase 2 | Active, not recruiting | May 17, 2022 |
| Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord InjurySpinal Cord Injuries, Myelopathy · Randy Trumbower, PT, PhD | Phase 1 / Phase 2 | Not yet recruiting | Feb 1, 2022 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 27, 2019 | NourianzNDA 22075 · New molecular entity | Kyowa Kirin | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Kyowa Kirin